Accuracy of the new rapid test for monitoring adalimumab levels

BACKGROUND: The loss of response to adalimumab (ADL) has been related to low serum concentrations at trough. Currently, most methods commercially available for the quantification of ADL are enzyme-linked immunosorbent assay (ELISA) based, with a turnaround time of approximately 8 h, delaying the tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, Cátia, Afonso, Joana, Lago, Paula, Arroja, Bruno, Vieira, Ana I., Dias, Claudia C., Magro, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393825/
https://www.ncbi.nlm.nih.gov/pubmed/30833984
http://dx.doi.org/10.1177/1756284819828238

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393825/
https://www.ncbi.nlm.nih.gov/pubmed/30833984
http://dx.doi.org/10.1177/1756284819828238

Ejemplares similares